Jingwen Shi

4PUBLICATIONS
25CO-AUTHORS
Molecular targetsChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 03, 2025
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

Zhihao Lu, Wenting Du, Xi Jiao

|Mar 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.

Jianming Xu, Ken Kato, Richard Hubner

|Apr 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.

Lin Shen, Ken Kato, Sung-Bae Kim

|Dec 02, 2021
Virtual memory T cells orchestrate extralymphoid responses conducive to resident memory.

Shiyue Hou, Tiange Shao, Tianyang Mao

Pageof 1

Frequent Collaborators

3 joint publications

Eric Van Cutsem

2 joint publications

Lin Shen

2 joint publications

Ken Kato

2 joint publications

Hiroki Hara